All In MedTech

Device Trial Radar · NCT04952610

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

130

Actual

Start

Dec 13, 2021

Primary completion

Apr 10, 2026

Study completion Apr 10, 2026

Sponsor

Lead sponsor
Milestone Pharmaceuticals Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 7, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.

Conditions

  • Paroxysmal Supraventricular Tachycardia

Interventions

  • Etripamil NS 70 mgDrug

    Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.

  • Aptar Pharma Nasal Spray Bidose SystemDevice

    Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of self-administered etripamil Nasal Spray (NS) for treatment of episodes of PSVT outside of the clinical setting as assessed by patient-reported adverse events.Time frame: Up to 3 years

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Site # 0160

    Little Rock, Arkansas

  • Site # 1023

    Vista, California

  • Site # 1083

    West Hills, California

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.